Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.

Staplin N. et al, (2021), EClinicalMedicine, 41

Acute treatment effects on GFR in randomized clinical trials of kidney disease progression

HERRINGTON W., (2021), Journal of the American Society of Nephrology

Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults.

Thomson B. et al, (2021), Int J Epidemiol, 50, 955 - 964

Association of kidney function with NMR-quantified lipids, lipoproteins, and metabolic measures in Mexican adults.

Aguilar-Ramirez D. et al, (2021), J Clin Endocrinol Metab

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter-2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter-2 inhibitors

HERRINGTON W. et al, (2021), European Journal of Heart Failure

Spinning the legs and blood: should intradialytic exercise be routinely offered during maintenance haemodialysis?

Graham-Brown MPM. et al, (2021), Clin Kidney J, 14, 1297 - 1300

Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression.

Neuen BL. et al, (2021), American journal of kidney diseases : the official journal of the National Kidney Foundation

Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998-2004 and 2015-2019.

Aguilar-Ramirez D. et al, (2021), Diabetes Care, 44, 944 - 951

Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults.

Gnatiuc L. et al, (2021), Eur J Prev Cardiol

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

COMBINED CHANGES IN GLOMERULAR FILTRATION RATE AND ALBUMINURIA AND RISK OF KIDNEY DISEASE PROGRESSION IN ROUTINE CLINICAL PRACTICE

Neuen B. et al, (2020), NEPHROLOGY, 25, 23 - 24

Conventional and Genetic Evidence on the Association between Adiposity and CKD.

Zhu P. et al, (2020), J Am Soc Nephrol

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Levin A. et al, (2020), Kidney International, 98, 849 - 859

Pre-randomization run-in periods in randomized controlled trials of chronic diseases: a methodological study.

Collister D. et al, (2020), J Clin Epidemiol

CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE

HERRINGTON W. et al, (2020), Journal of the American Society of Nephrology

Association of Blood Pressure With Cause-Specific Mortality in Mexican Adults.

Tapia-Conyer R. et al, (2020), JAMA Netw Open, 3

Blood pressure and kidney disease: chicken or egg (or both)?

Staplin N. et al, (2020), Kidney Int, 98, 547 - 549

In patients with coronary disease and CKD, adding an invasive strategy to MT did not improve outcomes.

Herrington WG. and Staplin N., (2020), Ann Intern Med, 173

In patients with coronary disease and CKD, initial invasive therapy did not improve angina-related health status.

Herrington WG. and Staplin N., (2020), Ann Intern Med, 173

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG. et al, (2020), Clin Kidney J, 13

Load More

1
2
3
4
5
6

Include forthcoming?